\<- [Anatomy of an Epidemic Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America](Anatomy%20of%20an%20Epidemic%20Magic%20Bullets,%20Psychiatric%20Drugs,%20and%20the%20Astonishing%20Rise%20of%20Mental%20Illness%20in%20America.md)

## Anatomy of an Epidemic Magic Bullets, Psychiatric Drugs, and the Astonishing Rise of Mental Illness in America 5. The Hunt for Chemical Imbalances

[ ![150](%E2%9A%99%EF%B8%8F%20Tools/%F0%9F%93%B8%20Images/97009FFA-D9B3-4ED1-A076-0711A2DB6D40.jpeg) ](https://www.amazon.com/gp/aw/d/B0036S4EGE/ref=tmm_kin_swatch_0?ie=UTF8&qid=1666045897&sr=8-1)

Author: [Robert Whitaker]()
Publisher: New York , NY: *Crown Publishing*.
Publish Date: 2010-3-31
Review Date:
Status: #â˜ï¸/ðŸ“š 

---

### Annotations

104

However, even as Snyder and Seeman were reporting their results, Malcolm Bowers was announcing findings that cast a cloud over the dopamine hypothesis. He had measured the level of dopamine metabolites in the cerebrospinal fluid of unmedicated schizophrenics and found them to be quite normal. â€œOur findings,â€ he wrote, â€œdo not furnish neurochemical evidence for an over-arousal in these patients emanating from a midbrain dopamine system.â€17 Others soon reported similar results. In 1975, Robert Post at the NIMH determined that HVA levels in the cerebrospinal fluid of twenty unmedicated schizophrenics â€œwere not significantly different from controls.â€18 Autopsy studies also revealed that the brain tissue of drug-free schizophrenics did not have abnormal levels of dopamine. In 1982, UCLAâ€™s John Haracz reviewed this body of research and drew the obvious bottom-line conclusion: â€œThese findings do not support the presence of elevated dopamine turnover in the brains of \[unmedicated\] schizophrenics.â€19

17. M. Bowers, â€œCentral dopamine turnover in schizophrenic syndromes,â€ Archives of General Psychiatry 31 (1974): 50â€“54.

17. R. Post, â€œCerebrospinal fluid amine metabolites in acute schizophrenia,â€ Archives of General Psychiatry 32 (1975): 1063â€“68.

17. J. Haracz, â€œThe dopamine hypothesis: an overview of studies with schizophrenic patients,â€ Schizophrenia Bulletin 8 (1982): 438â€“58.

---

105

Having discovered that dopamine levels in never-medicated schizophrenics were normal, researchers turned their attention to a second possibility. Perhaps people with schizophrenia had an overabundance of dopamine receptors. If so, the postsynaptic neurons would be â€œhypersensitiveâ€ to dopamine, and this would cause the dopaminergic pathways to be overstimulated. In 1978, Philip See-man at the University of Toronto announced in Nature that this was indeed the case. At autopsy, the brains of twenty schizophrenics had 70 percent more D2 receptors than normal. At first glance, it seemed that the cause of schizophrenia had been found, but Seeman cautioned that all of the patients had been on neuroleptics prior to their deaths. â€œAlthough these results are apparently compatible with the dopamine hypothesis of schizophrenia in general,â€ he wrote, the increase in D2 receptors might â€œhave resulted from the long-term administration of neuroleptics.â€20

20. T. Lee, â€œBinding of 3H-neuroleptics and 3H-apomorphine in schizophrenic brains,â€ Nature 374 (1978): 897â€“900.

105

A variety of studies quickly proved that the drugs were indeed the culprit. When rats were fed neuroleptics, their D2 receptors quickly increased in number.21 If rats were given a drug that blocked D1 receptors, that receptor subtype increased in density.22 In each instance, the increase was evidence of the brain trying to compensate for the drugâ€™s blocking of its signals. Then, in 1982, Angus MacKay and his British colleagues reported that when they examined brain tissue from forty-eight deceased schizophrenics, â€œthe increases in \[D2\] receptors were seen only in patients in whom neuroleptic medication had been maintained until the time of death, indicating that they were entirely iatrogenic \[drug-caused\].â€23 A few years later, German investigators reported the same results from their autopsy studies.24 Finally, investigators in France, Sweden, and Finland used positron emission topography to study D2-receptor densities in living patients who had never been exposed to neuroleptics, and all reported â€œno significant differencesâ€ between the schizophrenics and â€œnormal controls.â€25

21. D. Burt, â€œAntischizophrenic drugs: chronic treatment elevates dopa mine receptor binding in brain,â€ Science 196 (1977): 326â€“27.

21. M. Porceddu, â€œ\[3H\]SCH 23390 binding sites increase after chronic blockade of d-1 dopamine receptors,â€ European Journal of Pharmacology 118 (1985): 367â€“70.

21. A. MacKay, â€œIncreased brain dopamine and dopamine receptors in schizophrenia,â€ Archives of General Psychiatry 39 (1982): 991â€“97.

21. J. Kornhuber, â€œ3H-spiperone binding sites in post-mortem brains from schizophrenic patients,â€ Journal of Neural Transmission 75 (1989): 1â€“10.

21. J. Martinot, â€œStriatal D2 dopaminergic receptors assessed with positron emission tomography and bromospiperone in untreated schizophrenic patients,â€ American Journal of Psychiatry 147 (1990): 44â€“50; L. Farde, â€œD2 dopamine receptors in neuroleptic-naÃ¯ve schizophrenic patients,â€ Archives of General Psychiatry 47 (1990): 213â€“19; J. Hietala, â€œStriatal D2 dopamine receptor characteristics in neuroleptic-naÃ¯ve schizophrenic patients studied with positron emission tomography,â€ Archives of General Psychiatry 51 (1994): 116â€“23.

---

99

In a study of eight depressed patients (all of whom had been previously exposed to antidepressants), he announced that their 5-HIAA levels were lower than normal, but not â€œsignificantlyâ€ so.3 Two years later, investigators at McGill University said that they, too, had failed to find a â€œstatistically significantâ€ difference in the 5-HIAA levels of depressed patients and normal controls, and that they also had failed to find any correlation between 5-HIAA levels and the severity of depressive symptoms.4 In 1974, Bowers was back with a more finely tuned follow-up study: Depressed patients who had not been exposed to antidepressants had perfectly normal 5-HIAA levels.5

3. M. Bowers, â€œCerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in psychiatric patients,â€ International Journal of Neuropharmacology 8 (1969): 255â€“62.

3. R. Papeschi, â€œHomovanillic and 5-hydroxyindoleacetic acid in cerebrospinal fluid of depressed patients,â€ Archives of General Psychiatry 25 (1971): 354â€“58.

3. M. Bowers, â€œLumbar CSF 5-hydroxyindoleacetic acid and homovanillic acid in affective syndromes,â€ Journal of Nervous and Mental Disease 158 (1974): 325â€“30.

---

100

It seemed that the theory was about to be declared dead and buried, but then, in 1975, Marie Asberg and her colleagues at the Karolinska Institute in Stockholm breathed new life into it. Twenty of the sixty-eight depressed patients they had tested suffered from low 5-HIAA levels, and these low-serotonin patients were somewhat more suicidal than the rest, with two of the twenty eventually committing suicide. This was evidence, the Swedish researchers said, that there might be â€œa biochemical subgroup of depressive disorder characterized by a disturbance of serotonin turnover.â€8 Soon prominent psychiatrists in the United States were writing that â€œnearly 30 percentâ€ of depressed patients had been found to have low serotonin levels. The serotonin theory of depression seemed at least partly vindicated.

8. M. Asberg, â€œSerotonin depression: A biochemical subgroup within the affective disorders?â€ Science 191 (1976): 478â€“80; M. Asberg, â€œ5-HIAA in the cerebrospinal fluid,â€ Archives of General Psychiatry 33 (1976): 1193â€“97.

8. J. Mendels, â€œBrain biogenic amine depletion and mood,â€ Archives of General Psychiatry 30 (1974): 447â€“51.

8. D. L. Davies, â€œReserpine in the treatment of anxious and depressed patients,â€ Lancet 2 (1955): 117â€“20.

100

But today, if we revisit Asbergâ€™s study and examine her data, we can see that her finding of a â€œbiological subgroupâ€ of depressed patients was mostly a story of wishful thinking. In her study, Asberg reported that 25 percent of her â€œnormalâ€ group had cerebrospinal 5-HIAA levels below fifteen nanograms per milliliter. Fifty percent had fifteen to twenty-five nanograms of 5-HIAA per milliliter, and the remaining 25 percent had levels above twenty-five nanograms. The bell curve for her â€œnormalsâ€ showed that 5-HIAA levels were quite variable. But what she failed to note in her discussion was that the bell curve for the sixty-eight depressed patients in her study was almost exactly the same. Twenty-nine percent (twenty of the sixty-eight) had 5-HIAA counts below fifteen nanograms, 47 percent had levels between fifteen and twenty-five nanograms, and 24 percent had levels above twenty-five nanograms. Twenty-nine percent of depressed patients may have had â€œlowâ€ levels of serotonin metabolites in their cerebrospinal fluid (this was her â€œbiological subgroupâ€), but then so did 25 percent of â€œnormalâ€ people. The median level for normals was twenty nanograms, and, it so turned out, more than half of the depressed patientsâ€”thirty-seven of sixty-eightâ€”had levels above that amount. Viewed in this way, her study had not provided any new reason to believe in the serotonin theory of depression. Japanese investigators soon revealed, in an unwitting way, the faulty logic at work. They reported that some antidepressants (used in Japan) blocked serotonin receptors, inhibiting the firing of those pathways, and thus they reasoned that depression might be caused by an â€œexcess of free serotonin in the synaptic cleft.â€9 They had applied the same backwards reasoning that had given rise to the low-serotonin theory of depression, and if the Japanese scientists had wanted to, they could have pointed to Asbergâ€™s study for support of their theory, as the Swedes had found that 24 percent of depressed patients had â€œhighâ€ levels of serotonin.

9. H. Nagayama, â€œPostsynaptic action by four antidepressive drugs in an animal model of depression,â€ Pharmacology Biochemistry and Behavior 15 (1981): 125â€“30. Also see H. Nagayama, â€œAction of chronically administered antidepressants on the serotonergic postsynapse in a model of depression,â€ Pharmacology Biochemistry and Behavior 25 (1986): 805â€“11.

---

102

In 1984, NIMH investigators studied the low-serotonin theory of depression one more time. They wanted to see whether the â€œbiological subgroupâ€ of depressed patients with â€œlowâ€ levels of serotonin were the best responders to an antidepressant, amitriptyline, that selectively blocked its reuptake. If an antidepressant was an antidote to a chemical imbalance in the brain, then amitriptyline should be most effective in that subgroup. But, lead investigator James Maas wrote, â€œcontrary to expectations, no relationships between cerebrospinal 5-HIAA and response to amitriptyline were found.â€10 Moreover, he and the other NIMH researchers discoveredâ€”just as Asberg hadâ€”that 5-HIAA levels varied widely in depressed patients. Some had high levels of serotonin metabolites in their cerebrospinal fluid, while others had low levels. The NIMH scientists drew the only possible conclusion: â€œElevations or decrements in the functioning of serotonergic systems per se are not likely to be associated with depression.â€\*

10. J. Maas, â€œPretreatment neurotransmitter metabolite levels and response to tricyclic antidepressant drugs,â€ American Journal of Psychiatry 141 (1984): 1159â€“71.

---

103

Even after this report, the serotonin theory of depression did not completely go away. The commercial success of Prozac, a â€œselective serotonin reuptake inhibitorâ€ brought to market in 1988 by Eli Lilly, fueled a new round of public claims that depression was due to low levels of this neurotransmitter, and once again any number of investigators conducted experiments to see if that were so. But this second round of studies produced the same results as the first. â€œI spent the first several years of my career doing full-time research on brain serotonin metabolism, but I never saw any convincing evidence that any psychiatric disorder, including depression, results from a deficiency of brain serotonin,â€ said Stanford psychiatrist David Burns in 2003.11 Numerous others made this same point. â€œThere is no scientific evidence whatsoever that clinical depression is due to any kind of biological deficit state,â€ wrote Colin Ross, an associate professor of psychiatry at Southwest Medical Center in Dallas, in his 1995 book, Pseudoscience in Biological Psychiatry.12 In 2000, the authors of Essential Psychopharmacology told medical students â€œthere is no clear and convincing evidence that monoamine deficiency accounts for depression; that is, there is no â€˜realâ€™ monoamine deficit.â€13 Yet, fueled by pharmaceutical advertisements, the belief lived on, and it caused Irish psychiatrist David Healy, who has written a number of books on the history of psychiatry, to quip in 2005 that this theory needed to be put into the medical dustbin, where other such discredited theories can be found. â€œThe serotonin theory of depression,â€ he wrote, with evident exasperation, â€œis comparable to the masturbatory theory of insanity.â€14

---

115

Antipsychotics, antidepressants, and other psychotropic drugs, he wrote, â€œcreate perturbations in neurotansmitter functions.â€ In response, the brain goes through a series of compensatory adaptations. If a drug blocks a neurotransmitter (as an antipsychotic does), the presynaptic neurons spring into hyper gear and release more of it, and the postsynaptic neurons increase the density of their receptors for that chemical messenger. Conversely, if a drug increases the synaptic levels of a neurotransmitter (as an antidepressant does), it provokes the opposite response: The presynaptic neurons decrease their firing rates and the postsynaptic neurons decrease the density of their receptors for the neurotransmitter. In each instance, the brain is trying to nullify the drugâ€™s effects. â€œThese adaptations,â€ Hyman explained, â€œare rooted in homeostatic mechanisms that exist, presumably, to permit cells to maintain their equilibrium in the face of alterations in the environment or changes in the internal milieu.â€

116

However, after a period of time, these compensatory mechanisms break down. The â€œchronic administrationâ€ of the drug then causes â€œsubstantial and long-lasting alterations in neural function,â€ Hyman wrote. As part of this long-term adaptation process, there are changes in intracellular signaling pathways and gene expression. After a few weeks, he concluded, the personâ€™s brain is functioning in a manner that is â€œqualitatively as well as quantitatively different from the normal state.â€

116

what science had revealed was this: Prior to treatment, patients diagnosed with schizophrenia, depression, and other psychiatric disorders do not suffer from any known â€œchemical imbalance.â€ However, once a person is put on a psychiatric medication, which, in one manner or another, throws a wrench into the usual mechanics of a neuronal pathway, his or her brain begins to function, as Hyman observed, abnormally.

---

117

Thorazine, Miltown, and Marsilid were all derived from compounds that had been developed for other purposesâ€”for use in surgery or as possible â€œmagic bulletsâ€ against infectious diseases. Those compounds were then found to cause alterations in mood, behavior, and thinking that were seen as helpful to psychiatric patients. The drugs, in essence, were perceived as having beneficial side effects. They perturbed normal function, and that understanding was reflected in the initial names given to them.

117

psychiatry then reconceived the drugs as â€œmagic bulletsâ€ for mental disorders, the drugs hypothesized to be antidotes to chemical imbalances in the brain. But that theory, which arose as much from wishful thinking as from science, was investigated and it did not pan out.

---

115

Today, as provost of Harvard University, Steve Hyman is mostly engaged in the many political and administrative tasks that come with leading a large institution. But he is a neuroscientist by training, and in 1996 to 2001, when he was the director of the NIMH, he wrote a paper, one both memorable and provocative in kind, that summed up all that had been learned about psychiatric drugs. Titled â€œInitiation and Adaptation: A Paradigm for Understanding Psychotropic Drug Action,â€ it was published in the American Journal of Psychiatry, and it told of how all psychotropic drugs could be understood to act on the brain in a common way.46

46. S. Hyman, â€œInitiation and adaptation: A paradigm for understanding psychotropic drug action,â€ American Journal of Psychiatry 153 (1996): 151â€“61.

110

once a presynaptic neuron has released serotonin into the synaptic gap, it must be quickly removed so that the signal can be crisply terminated. An enzyme metabolizes a small amount; the rest is pumped back into the presynaptic neuron, entering via a channel known as SERT (serotonin reuptake transport). Fluoxetine blocks this reuptake channel, and as a result, Eli Lilly scientist James Clemens wrote in 1975, it causes a â€œpile-up of serotonin at the synapse.â€36

36. R. Fuller, â€œEffect of an uptake inhibitor on serotonin metabolism in rat brain,â€ Life Sciences 15 (1974): 1161â€“71.

110

However, as the Eli Lilly investigators discovered, a feedback mechanism then kicks in. The presynaptic neuron has â€œauto-receptorsâ€ on its terminal membrane that monitor the level of serotonin in the synapse. If serotonin levels are too low, one scientist quipped, these autoreceptors scream â€œturn on the serotonin machine.â€ If serotonin levels are too high, they scream â€œturn it off.â€ This is a feedback loop designed by evolution to keep the serotonergic system in balance, and fluoxetine triggers the latter message. With serotonin no longer being whisked away from the synapse, the autoreceptors tell the presynaptic neurons to fire at a dramatically lower rate. They begin to release lower-than-normal amounts of serotonin into the synapse. Feedback mechanisms also change the postsynaptic neurons. Within four weeks, the density of their serotonin receptors drops 25 percent below normal, Eli Lilly scientists reported in 1981.37 Other investigators subsequently reported that â€œchronic fluoxetine treatmentâ€ may lead to a 50 percent reduction in serotonin receptors in certain areas of the brain.38 As a result, the post synaptic neurons become â€œdesensitizedâ€ to the chemical messenger.

37. D. Wong, â€œSubsensitivity of serotonin receptors after long-term treatment of rats with fluoxetine,â€ Research Communications in Chemical Pathology and Pharmacology 32 (1981): 41â€“51.

37. J. Wamsley, â€œReceptor alterations associated with serotonergic agents,â€ Journal of Clinical Psychiatry 48, suppl. (1987): 19â€“25.

111

At this point, it may seem that the brain has successfully adapted to the drug. Fluoxetine blocks the normal reuptake of serotonin from the synapse, but the presynaptic neurons then begin releasing less serotonin and the postsynaptic neurons become less sensitive to serotonin and thus donâ€™t fire so readily. The drug was designed to accelerate the serotonergic pathway; the brain responded by putting on the brake. It has kept its serotonergic pathway more or less in balance, an adaptive response that researchers have dubbed â€œsynaptic resilience.â€39 However, there is one other change that occurs during this initial two-week period, and it ultimately short-circuits the brainâ€™s compensatory response. The autoreceptors for serotonin on the presynaptic neurons decline in number. As a result, this feedback mechanism becomes partially disabled, and the â€œturn off the serotonin machineâ€ message dims. The presynaptic neurons begin to fire at a normal rate again, at least for a while, and to release more serotonin than normal each time. 40

40. C. Montigny, â€œModification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers,â€ Journal of Clinical Psychiatry 51, suppl. B (1990): 4â€“8.

112

the Eli Lilly researchers reasoned in 1981 that it was the decline in serotonin receptors, which took several weeks to occur, that was â€œthe underlying mechanism associated with the therapeutic response.â€41 If so, the drug could be said to work because it drove the serotonergic system into a less responsive state. But once researchers discovered that fluoxetine partially disabled the feedback mechanism, Claude de Montigny at McGill University argued that this was what allowed the drug to begin working. This disabling process also took two or three weeks to occur, and it allowed the presynaptic neurons to begin pumping higher amounts of serotonin than normal into the synapse. At that point, with fluoxetine continuing to block serotoninâ€™s removal, the neurotransmitter could now indeed â€œpile upâ€ in the synapse, and that would lead â€œto an enhancement of central serotonergic neurotransmission,â€ de Montigny wrote.

41. D. Wong, â€œSubsensitivity of serotonin receptors after long-term treatment of rats with fluoxetine,â€ Research Communications in Chemical Pathology and Pharmacology 32 (1981): 41â€“51.

41. C. Montigny, â€œModification of serotonergic neuron properties by long-term treatment with serotonin reuptake blockers,â€ Journal of Clinical Psychiatry 51, suppl. B (1990): 4â€“8.

113

the medicine clearly doesnâ€™t fix a chemical imbalance in the brain. Instead, it does precisely the opposite. Prior to being medicated, a depressed person has no known chemical imbalance. Fluoxetine then gums up the normal removal of serotonin from the synapse, and that triggers a cascade of changes, and several weeks later the serotonergic pathway is operating in a decidedly abnormal manner. The presynaptic neuron is putting out more serotonin than usual. Its serotonin reuptake channels are blocked by the drug. The systemâ€™s feedback loop is partially disabled. The postsynaptic neurons are â€œdesensitizedâ€ to serotonin. Mechanically speaking, the serotonergic system is now rather mucked up.

---

114

During the 1970s and 1980s, researchers studying the effects of neuroleptics fleshed out a similar story. Thorazine and other standard antipsychotics block 70 to 90 percent of all D2 receptors in the brain. In response, the presynaptic neurons begin pumping out more dopamine and the postsynaptic neurons increase the density of their D2 receptors by 30 percent or more. In this manner, the brain is trying to â€œcompensateâ€ for the drugâ€™s effects so that it can maintain the transmission of messages along its dopaminergic pathways. However, after about three weeks, the pathwayâ€™s feedback mechanism begins to fail, and the presynaptic neurons begin to fire in irregular patterns or turn quiescent. It is this â€œinactivationâ€ of dopaminergic pathways that â€œmay be the basis for the antipsychotic action,â€ explains the American Psychiatric Associationâ€™s Textbook of Psychopharmacology.45

45. Schatzberg, Textbook of Psychopharmacology, 619.

114

Once again, this is a story of neurotransmitter pathways that have been transformed by the medication. After several weeks, their feedback loops are partially disabled, the presynaptic neurons are releasing less dopamine than normal, the drug is thwarting dopamineâ€™s effects by blocking D2 receptors, and the postsynaptic neurons have an abnormally high density of these receptors. The drugs do not normalize brain chemistry, but disturb it,

107

This became the storytelling formula that was relied upon by pharmaceutical companies again and again: Researchers would identify the mechanism of action for a class of drugs, how the drugs either lowered or raised levels of a brain neurotransmitter, and soon the public would be told that people treated with those medications suffered from the opposite problem.

108

Psychopharmacology, was embraced by psychiatrists because it â€œset the stageâ€ for them â€œto become real doctors.â€31 Doctors in internal medicine had their antibiotics, and now psychiatrists could have their â€œanti-diseaseâ€ pills too.

---

### Notes
